Pfizer-BioNTech said they are expecting to start Covid-19 vaccine studies in children aged five to 11 in the next couple of months, according to a company news release.
The companies said they also have plans to study the vaccine in children younger than five later this year.
Pfizer-BioNTech’s current trial – for children aged 12 to 15 – began enrolling participants in October of last year. That trial is now fully enrolled and the companies say “the relevant data are planned to be submitted to the regulatory authorities in the second quarter of 2021.”
Currently, Pfizer’s Covid-19 vaccine has been granted emergency use authorization by the US Food and Drug Administration for those who are aged 16 and above. There is currently no FDA authorized Covid-19 vaccine for children.